Architect Therapeutics
San Diego, US · 2 known investors
Find your way into Architect Therapeutics
190 people in our graph share verified history with the Architect Therapeutics team — schools, employers, funds. One of them is your warm intro.
Brittany de Kouchkovskyunlockedknows Richard Heyman · together at Salk Institute for Biological Studies (overlapped)
×9knows the team · via ARCH Venture Partners
knows the team · via Vividion Therapeutics
knows the team · via Metacrine
Architect Therapeutics is a drug discovery company that uses C-H bond activation chemistry to synthesize novel 3D small-molecule scaffolds and screen them against difficult-to-drug targets. It develops oral therapies with an emphasis on immunology and oncology.
Founders & leadership
JY
JY
Jin-Quan Yu, Ph.D.Scientific Founder
BC
Ben Cravatt Ph.D.Scientific Founder
RH
Rich Heyman, Ph.D.Scientific Founder
AY
Angie You, Ph.D.Chief Executive Officer
Investors · 2
In the news
Frequently asked questions
- What does Architect Therapeutics do?
- Architect Therapeutics is a drug discovery company that uses C-H bond activation chemistry to synthesize novel 3D small-molecule scaffolds and screen them against difficult-to-drug targets. It develops oral therapies with an emphasis on immunology and oncology.
- Who founded Architect Therapeutics?
- Architect Therapeutics was founded by Jin-Quan Yu, Jin-Quan Yu, Ph.D., Ben Cravatt Ph.D., Rich Heyman, Ph.D..
- Who are Architect Therapeutics's investors?
- Architect Therapeutics's investors include Frazier Life Sciences, OrbiMed.
- Where is Architect Therapeutics headquartered?
- Architect Therapeutics is headquartered in San Diego, US.